Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Indutrade, Audiocast with teleconference, Q1'24

By Inderes4/25/2024, 7:30 AM
Indutrade

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Bo Annvik
00:02 - 21:02

Welcome and good morning on our behalf as well. We will directly go into some of the overall highlights as usual. And we have, uh, we gave this quarterly report the headline 'Stable Demand in a Challenging Quarter'. And by challenging we referred to, uh, that Q1 in 2023 was a very strong quarter and is now a difficult reference. We have some Easter effect and uh, also some headwind in certain segments and all of this I will obviously elaborate more on. But back to the highlights and the comments. So there was a stable order intake growth of plus 0% in total, whereof -3% organically. And to comment on some of the. Sectors and segments. We saw good demand in the med tech area. Pharmaceutical area. And also in terms of energy and the process industry. In terms of sales, we were down 4% and organically -6%. And again, this was mainly due to strong references and fewer working days. This led to an EBITA margin of 13.3%. Not a level where we want to be. But again, I will talk a bit more about this later on here. The inventory level was quite stable from Q4 2023, so sequentially flat. And a very good acquisition pace. Five acquisitions completed in quarter one and seven so far in the year here. And I would say that the inflow of interesting companies to acquire is strong. But I'm sure many of you are keen to understand more about the market perspective. And, uh. On this slide here, you see both order intake and sales next to each other. And, uh. The bars refer to the absolute numbers, and the yellow line is, uh, the growth line organically. Uh, and you can see now, in terms of the bars there that we have had a growing order intake, uh, and a fairly good order intake in Q4, uh, last year and Q1 now this year in relation to, to sales, which, uh, which has been a little bit weaker there, and hence we have built some, some order book. Uh. But, uh, I would say continued, uh, aggregated stable, high demand and, uh, order intake, as I said, in line with previous year and Q4 2023. And just to give some context to 2023 order intake. At that point in quarter one was in total up 14% and organically plus 3%. And as usual for Indutrade, we have seen variation between companies, segments, and countries. And we have had a positive book to build now two quarters in a row, where orders now were 4% higher than sales. So, you have to take the numbers. Plus 0% in total, -3% organically, plus 3% from acquisitions. Minus 1% from divestments and plus 1% related to currency. And, talking a bit about sectors and segments. As I said, companies with customers in pharmaceutical production had their strongest order intake. Demand was also good within the process industry and the energy segment. As many of you know, we have a cluster of companies linked to the Novo Nordisk capacity increases. And that's still obviously ongoing to a very large extent. But the projects are large and complex, and there are some delays being experienced there. So, I would say that we weren't able really to invoice and ship to the extent which we had planned some months ago. In general, I've said this many times before. In general, the green transformation is still driving a lot of investments and also business activity in general, which is positive for a large part of our companies, not least the process, energy, and water business area. The organic order intake in infrastructure and construction was still weak and has been weak now for some quarters, predominantly in the construction area. This quarter, we have also experienced a bit weaker demand from the engineering segment. If we then turn to sales. Again, strong references. And it was even stronger on the sales side than the order intake side. Q1 2024 sales increased 26% in total and plus 13% organically. So, it's really difficult comparisons here. And we came in this quarter -4% in total and -6% organically, plus 3% from acquisitions, -1% from divestments and the impact from currency was basically flat. And this time, only one of our five business areas was able to grow organically. And that was process, energy, and water. And again, based on, to a large extent, I would say, the green transformation and predominantly the Nordic region, Life Science had very strong references, a lot of all-time highs in our companies in terms of sales last year. And again, as I said, there's a bit of delays linked to the Novo Nordisk, potential invoicing, shipping, and also lower activity in terms of single-use in the pharma production, we had a great business linked to that a year ago. And now it's dramatically lower. And part of that can be explained by less. With orientation. And again, a continued challenging market situation for the infrastructure and construction area. If we look at sales more in a market perspective, what market countries we sell into. You see that we have divided this into a Nordic cluster, something we call rest of Europe, and then rest of the world. And there, we are, since several quarters back, stronger or we are experiencing a stronger market situation in the Nordics versus the more central European countries. Uh, and within the Nordics, it's actually this quarter been Norway, which has been the best market. And in Norway, I would say that the energy segment stands out positively and otherwise. It's a rather okay situation overall. Otherwise, Sweden, Denmark, Finland were more flattish. Obviously, differences between sectors in these countries. In Sweden, we have had a good life science situation, but the construction sector was weak; the rest has been more flattish in Denmark. It's been quite okay in terms of process, energy, and water. Some of our companies there have built new business in Iceland where we really haven't been strongly present before, which has been positive. And, as I said, Denmark would probably have been a little bit stronger with an arrow up if there had been more invoicing linked to this Novo Nordisk cluster in Finland, we also see a weaker construction area, also slightly weaker engineering segment. And obviously there's been a strike, as you all know, in Finland this quarter. And that has also had some impact there. And if we turn to the rest of Europe, it is somewhat weaker. In the Benelux area and Germany, we see weaker single-use invoicing. And that's sort of driving the arrows down otherwise fairly flattish situations in the UK. Energy and defence are positive, construction weaker. In Switzerland and to some extent, Austria. We have also seen a weaker situation in the construction segment. Also life science and process, energy, and water. And we are not really present in the other sectors in Switzerland, Austria. You're fairly relatively small in North America and Asia, so large individual orders can have some impact. But, in general, the business climate is stronger in North America. That's why the arrow is up there. And, in Asia, prominently China, a bit of a weaker business situation. If we then turn to our financial performance in terms of EBIT, obviously the organic sales development is the main driver for the EBIT decline. Again, the strong references and the Easter effects had an impact there; in absolute terms, our EBITA came in at 1.1 billion SEK, a decrease of 16% and 19% organically, and plus 3% from acquisitions, 0% from divestments, and 0% linked to currency. It was actually comforting to see that our gross margin was improving this quarter. It's actually been our best gross margin level since Q4 2021. So good work in terms of that. However, we also experienced higher expense levels. And here we are not equally proud. And, uh, I could say that cost management will be important, uh, going forward. I think we, uh, were a little bit too much on our heels versus on our toes in this quarter. Linked to the cost side. All of you basically know that from the beginning of the year, we introduced a new, uh, group structure. Uh, we went from eight business areas to five international business areas. And, uh, the intention with this is, uh, basically to fuel, uh, growth medium term, long term, not any expected short term impact. And, uh, the organization is obviously launched and implemented, and the structure is based on being more outside-in market-driven in terms of these new sectors. And all the sectors are then divided into approximately 30 segments. Uh, we have definitely still kept the individual company at the core of Indutrade. So we are more building a, you can say, a support and development structure around the companies. Uh, and the companies are now grouped into more relevant segments where they can learn from each other and gain knowledge from each other in a better way. We also think that this can and should drive positive acquisition activity. We can more clearly see now where we potentially have what we call white spot areas in these 30 segments and then build acquisition plans in a structured way linked to that. Uh, I also think this structure provides more clarity about the trading and external perspective. It's intuitively more, uh, easy, I would say to understand what, uh, what we are all about and in what sectors we are present. So if we then turn to the performance in the five different business areas, uh. I would say that all of them are obviously impacted by fewer working days and strong references, but in particular the life science area. They had an extremely strong, uh, quarter one last year and not least then linked to this single-use area. Infrastructure and construction continues to have a challenging market situation. And in this business area, total sales were also affected negatively by the divestment of the Dutch company Cubic, which we made late last year, and that had an impact of -8%. Uh, and this is not new, that there has been headwind in the construction sector for some quarters now. And, uh, I would also say that the winter this. Quarter or the quarter. First quarter of this year in the Nordics has been quite challenging in terms of construction work. The weaker general engineering and also construction work had an impact on industrial and engineering and also technology and system solutions more broadly. And uh, and uh, I would say more evidently this quarter than in 2023, uh, but, uh, process, energy, and water managed to grow organically and, and driven mainly by the process industry and the energy segments in the Nordic area. And if we look at the EBITA in a business area perspective, uh, all areas were impacted by the weak organic sales development and uh, EBITA margin declined for all business areas, but only very marginally for process, energy, and water. Life science, as discussed before, had the most challenging references and the lower organic sales for companies selling to the pharmaceutical production. Single-use had a really stronger impact on the margin here. Good pricing work and, uh, impacting the gross margin positively. And again, it came in at 35% versus 34.6% a year ago. So, strong level here. But the margin, the EBITA margin, was reduced or dampened by our increased expense level. And, we have obviously experienced cost inflation in general. And, this needs to be managed. And, I am not completely satisfied with our performance here this quarter. If we then leave the financials and the business areas and turn to acquisitions, more of a happy face, happy situation, I would say a really good start in 2024. And, we have now been able to acquire seven well-managed, successful companies. And if we add their total sales annually, it adds up to 775 million SEK. And, four out of five business areas have been engaged in acquisitions. And we have a number of projects right now in different phases ongoing, which is positive for the coming quarters. And as we have said before, we have generally strengthened our acquisition resources since some quarters now. And we have built also some professional resources in Northern Italy, and hope to see positive effects of that going forward. Also, the general pipeline remains strong, and the inflow of new companies is positive. So all in all, I'm quite optimistic that 2024 will be a good acquisition year. On this slide here, you can see our performance in terms of the number of companies acquired and also the quarterly financial effects from acquisitions. How much, basically how much EBITA we have added in a single quarter here. And, in the slide, towards the right, you see that we have added around 30 million SEK in quarter one. And, that's in relation to the previous years here, a fairly low level. We have been more around 60, 70, or even above that in some quarters. So we didn't have effects from previous quarters into this first quarter to a very large extent now. And the acquisitions we have made this quarter haven't really added enough yet. So, in this perspective, quarter two will have a better effect, more effect. But, you know that our goal is to really acquire around 20 companies per year. And I would say that we are at that pace this year now. And, in general, it's wise to basically follow our acquisition progress over a longer period of time since it can shift between quarters quite significantly. By that, I will leave the word over to Patrik to elaborate a little bit more about the financial performance. Yes. Thank you.

Patrik Johnson
21:02 - 28:05

Bo and, summarizing a little bit of the financial performance then and maybe repeating a bit, important key points. Total growth for orders. Sales were zero and minus four respectively, in the quarter. And, as we already talked about on the organic side, strong references and the effect of fewer working days had a negative impact on the development and also on the acquisition side, the additions from acquisitions were relatively low compared to previous quarters. Um, as the new acquisitions have not really, have not really started to give effect, so slightly lower than we're used to, but it will increase during the coming quarters. A positive aspect is that the book-to-bill ratio was above one in all business areas. And also then, aggregated, of course, 4% higher order intake than sales in the quarter. Continued good pricing work gave us a higher gross margin, as we also mentioned, 35 versus 34.6 last year. EBITA was down 16% in the quarter. Driven by the lower organic sales, I would say. And, slightly higher expenses. EBITA margin 13.3% versus 15.2% last year. Uh, and Q1 has historically been a seasonally low margin quarter. So the 15.2% last year really stands out. I must say that. And looking in detail at the results a little bit more. We had some positive earnout revelations in the quarter as we sometimes have, but then they were basically offset by some other negative one-offs, for instance, connected to the divestment Bo mentioned. So, there are no one-off effects in the result, I would say finance net is up 17% versus last year, because of the higher interest rates. Tax costs decreased by 23%. So basically, in line with the results, the underlying tax rate is also done, basically in line with last year's EPS decrease by 22% in the quarter. And I will elaborate a little bit more on the next slide about that return on capital employed decline. The EBITA margin is still on a good level of 20%, in line with our target. Cash flow from operations was seasonally weak in Q1 and amounted to 487, which is lower than last year. Also, that was affected mainly by the lower earnings. Note that EBITA was stable on a relatively low level, 1.5 versus 1.8 last year. So, moving on and looking at the cash flow. And as I said, it is also clear from this chart that Q1 is a seasonally low quarter. However, it was also down compared to previous years, and amounted to 487. And the decrease is driven entirely by the lower result. Working capital movements were actually more favorable this quarter than last year. Inventories, more specifically, were sequentially stable from the end of last year. Of course, a bit of a headwind when the organic sales. As a sort of slow development, but the companies are working hard to get the inventories further down. And then, maybe also important to note that Q1 is normally a quarter where working capital is increasing slightly, and that's part of the reason why cash flow is normally seasonally a bit low in Q1. So moving on to look at the earnings per share development from a trend perspective. And uh, EPS amounted to 1.61 in this quarter compared to 2.06 per share, uh, Q1 last year. And this was mainly driven by the lower operational result. Um, but also then of course, the increased finance costs also impacted this in a negative way as well. Looking at the longer-term perspective, the three-year and the five-year growth rates are 16% and 14%, respectively. And, uh, pending then with the debt situation. To summarize, we still have a strong financial position. The interest-bearing net debt decreased versus last year and was around 8.5 billion versus 9.4 billion last year. And, uh, the reduction there comes mainly from the very strong cash flow we had last year. Then the seasonally lower Q1 cash flow, in combination with the increased acquisition pace, made the debt move up sequentially, slightly. But the net debt ratios, they are still stable and low from a historical perspective, with equity at 55 versus 69. And that's about it, as I mentioned before, 1.5 versus 1.8 last year. And if you exclude the earnout, it's 1.4 versus 1.6 last year. So again, in conclusion, despite increasing our acquisition pace, the financial position is strong. So, then I'll hand it back over to you. But to summarize.

Bo Annvik
28:05 - 30:02

Thank you, Patrik. So, the key takeaways from this presentation here should be that. There has been stable demand in a challenging quarter and a positive book-to-bill two quarters in a row now. We have a portfolio of companies in different situations and companies experiencing better market conditions. They obviously continue to pursue growth initiatives, while companies with more declining order intake are actively working on defending their margins. There is still some uncertainty in terms of the macroeconomic situation. However, it seems like we are coming closer and closer to. To reduce interest rates. But there are also geopolitical risks which provide uncertainty. And, uh, we also face strong references, particularly now in quarter two; in quarters three and four, they will be more reasonable. However, the slightly improved order backlog and the good acquisition pace contribute to some optimism about the earnings trend in the coming quarters. Seven acquisitions in 2024, with combined annual sales of 775 million. And we have established and implemented a new group structure for future growth. I would say towards the end here that we are not happy with the Q1 profitability and we will work towards improving this level going forward. By that, we end the presentation, the formal presentation, and leave the word back to the facilitator.

Carl Boqvist
30:04 - 30:27

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Zeno Galen Ricchiuti from Handelsbanken. Please go ahead.

30:29 - 31:00

Thank you and thanks for taking our questions. Just to start off there on the margins, as you said, there are strong comps and maybe a bit higher cost than you had wanted, but would you say that, given the volumes that you have, the EBITA margins are kind of on a normalized level for a Q1, or is there more would there be more to that you could trim away on the cost side? You know, material ways of saying.

Bo Annvik
31:03 - 31:23

I would say that there is and should be. There should be more to do on the cost side. But, I can't give you sort of like a number, or what type of impact that should have. But there is more to do there.

Patrik Johnson
31:24 - 31:45

And, input is also that sales of course, the strong you have the strong reference, but you also have the working day. So, that lowers total sales, of course. And we will get back that in quarter two. So that will also impact the margin, of course.

31:47 - 31:56

Okay. And would you say that there is a material difference between the trading companies and those with proprietary products? That's worth highlighting.

Bo Annvik
31:57 - 32:29

No, I think it's, that categorization is not. Key here. It's more, I would say, different sectors and, the cost is more, more. More of a broader situation than, linked to a certain category of companies, I would say.

Patrik Johnson
32:30 - 32:41

Also, the gross margin indicates also that there's no sort of big ground or absorption or so in the production companies that impacts.

32:42 - 32:56

Very good. And just lastly, on life science on the project, which you were not maybe able to invoice as much as you had anticipated. Is it possible to get some kind of idea of the impact it had in the quarter?

Bo Annvik
32:58 - 33:19

Some. No, I can't give you a number there, but it has some impact. And it's, if it wasn't, to some extent, significant. I wouldn't have mentioned it. Okay.

33:19 - 33:20

Thank you. I'll get back in line.

Bo Annvik
33:21 - 33:21

Thanks.

Carl Boqvist
33:32 - 33:38

The next question comes from Carl Ransom from Nordica. Please go ahead.

Carl Ransom
33:41 - 34:34

Uh. Good morning. It's Carl from Nordica. Uh, coming back a bit on the SG&A level. I mean, looking at both selling and administrative expense up 8%. Uh, as you said, sales came down due to working days. Um, which impacts, obviously, the relation to sales, but could you give us a bit of a walkthrough of the components here? I mean, it looks a little bit steep in our view. I guess wage inflation is a bit of it, but I cannot obviously explain the whole SG&A uplift here. So, uh, and also on that note, I guess you mentioned a bit of cost-cutting. Could you explain a bit how you will communicate and work with the companies on the back of it? And also, will you, um, work a bit more with pricing because you have good pricing? Uh. Uh, I mean, you could likely work with pricing in some companies as well, I guess.

Bo Annvik
34:37 - 35:34

Yeah. No, as you say yourself, it's a general cost inflation increase, as we all know. And also linked to salaries and people-related costs. Uh, I would also say that since we have experienced quite good growth for several years now, some of our companies have engaged in facility changes and, for the right reasons. Uh, they've been growing and they've been outgrowing some of their old facilities and leased new facilities and so on. So there is, to some extent, I think, a cost increase linked to that. And, uh. Uh. Otherwise, I can't really say that I have any specific comments. I don't know, Patrik, if you have, uh, no.

Patrik Johnson
35:34 - 36:22

If you, uh uh, I mean, there's not that there's no increase in employees net, I would say year over year. So there's no big increase in employees. There is a structural cost, as Bo Annvik describes on the facility side that's driving a little bit. Companies have moved into a few companies and moved into a bigger structure. So that's part of it. Inflation, I would say the main other reason is that inflation that you mentioned than 7 or 8%, that's on the total and including acquisition and currency. So looking at the organic, it's I would say it's half of that, which is also a lot of money, but, but uh, um, yeah. And not as high as you describe.

Bo Annvik
36:23 - 36:57

And I think, how we work with it, you have fixed costs, you have semi-fixed, and you have variable costs. And of course, you can more easily decide on yourself in terms of activity-oriented costs, basically. And here I think companies could have done a little bit better job when they. When they were expecting, perhaps, a lower top line. They need to be a little bit more on their toes to protect their profit margins.

Carl Ransom
36:59 - 37:29

And in Indutrade, I mean, if you look at the historical context, you've been extremely good at managing costs, being very agile. Would you say that the reshuffling of companies is the reason behind this, sort of, maybe? Maybe the reason that you've taken out costs that quickly as before, or it could be that having too many companies to manage is a reason why. Or is it just bad luck this quarter? Or how should we look at it?

Bo Annvik
37:30 - 38:53

I think it's not primarily for the reasons you bring up because. Business areas or head office are not drivers for cost reductions. It should be the local managing directors who, along with their management teams, manage this. And I think it's perhaps a little bit more linked to that. We have had quite a long journey of growth now. Yes, perhaps a little bit. A little bit slow reaction here and there. More than, more. Than usual. But it's, uh. Yeah, I'm still confident that with some sort of discussions internally. Now we will very quickly come back to the DNA we have in the group here to manage costs in a good way. So I'm actually not really worried, but I think it's more of a. One slight setback here, but we will manage to come back to this in a good way. Responsibility lies locally and should continue to do so. So, it's not really linked to a new organization.

Carl Ransom
38:54 - 39:35

Hmm. Okay. Very good. And, um, also on Life Science here. We have very limited historical numbers, but from the historical data, the margin looks somewhat soft, but we obviously had good demand in the quarters. We can actually see from your reporting. So what this sort of could help us with is the historical margin. What is the normalized, I mean, the sort of boosted year-over-year margin level, and could you also help us on the year-over-year development here in the margin of life science? How is the mix effect with lower single-use demand currently?

Bo Annvik
39:37 - 41:14

Yes, it's a super relevant question, obviously. And, I will say that we will come back to that with a more structured answer. At the right time, we are in a phase of actually detailing this out ourselves. Obviously, we know a lot more than you do, but rather than saying something prematurely now, I think we will come back more. Yes, at the right time. When we have an overview which we can explain in a good way. Briefly, the single-use segment has been very accretive for us. Within single use. There was a clear Covid spike, and that is now basically gone. And it's difficult to short term offset that spike with other types of single-use orders that quickly. So I think that is the main explanation. I would say, and the single-use companies have been quite profitable. So when they, in absolute terms, have lower both top line and bottom line, there is a mixed effect in the Life Science business area, impacting the total area negatively. I don't know. Do you want to add, Patrik, anything linked to that?

Patrik Johnson
41:15 - 42:44

No. I'm maybe repeating a little bit, but there was fantastic organic growth in this segment. Not only specific Covid orders, but the whole area grew fantastically during 2021, 2022. Built up a very big backlog, with relatively long lead times. And that was delivered out in a very good way. Then late 2022 and beginning of 2023, contributing to the good results of Life Science last year and now, those orders or the backlog is more normalized or lower. It's I would say not normalized but low on the single-use side, we see some slight signs of pickup, but it will take some more quarters before it. Before it comes back more in good pace. So in general, I think the Life Science margin is, there is a potential to that. But we need to come back with maybe a more detailed answer on that, but I think there's for sure a potential to that up to something more similar to what they had before. But exactly what, let's come back to.

Bo Annvik
42:44 - 42:44

That.

Carl Ransom
42:45 - 43:16

And then the follow-up, if I may. Sorry. On the order intake in Life Science, you grew by 1% organically. And you said that you see some signs of a pickup. Do you have positive organic growth in Single-Use currently, or is it more an ambition perhaps in a few quarters? Or was the statement related to sales that you have a pickup in orders now and sales might improve as they can have when you deliver or.

Patrik Johnson
43:19 - 43:43

No, but if you look at the order intake, there is, I don't have the aggregated number to be honest, on the single use, but it's picking up sequentially at least. On the order side, but the sales side, it's a big negative in the quarter.

Carl Ransom
43:43 - 43:49

And what is the time difference between order and delivery, typically?

Bo Annvik
43:49 - 44:31

But I would say that's a more significant uptake, both in orders to start with and sales. Uh, it is a couple of quarters away in single use. There has been quite a lot of, uh. Of stock build-up by these customers, and so there's not going to be a really dramatic effect, I don't think, in Q2, perhaps not even in Q3, but more towards the end of the year, there is, as Patrik says, a positive trend. But, it's going to be more significant later on in the year.

Patrik Johnson
44:32 - 45:08

Then to zoom out. I mean, this is only one of the areas we have in the life science area. Then you have the cluster working with pharmaceutical production, but more stainless steel oriented pharmaceutical production, which has had a fantastic order growth last year. And even if there's maybe a flattening out this quarter because of a bit delay in Novo Nordisk, that will continue to grow. So there are other areas. This single use is, of course, not an insignificant area, but only one of the areas within Life Science.

Carl Ransom
45:10 - 45:23

I fully agree. But from the look of the margin, it looks to be quite, uh, quite important, right? That's the reason behind the questions, I guess. Uh, but it would be super helpful if we could come back to that point at some time. Thank you so much.

Bo Annvik
45:23 - 45:24

Thank you.

Carl Boqvist
45:27 - 45:34

The next question comes from Carl Boqvist from ABG Sundal Collier. Please go ahead.

45:36 - 46:09

Thank you and good morning. My first question is on the organic growth deceleration. If we compare it to the level we had now in Q4 2023. Just to understand the dynamics on a group level, more in terms of order intake and net sales and what you see, and also the comment you made about, you know, two quarters of the book-to-bill ratio and then encouraging earnings trend going forward two quarters in a row now, good order intake. How quickly could this help organic growth.

Bo Annvik
46:12 - 48:19

Uh, yeah. It's, uh. If we look at quarter two to be a little bit more specific, then I think the Easter effect will definitely, obviously have a very positive impact. And the number of days, the number of working days effect and. So, even if we are basically flat. At the level where we were being invoiced on a daily basis, in March. Now, there will, in absolute terms, be a positive effect in quarter two, which is probably quite significant. And then we will see a little bit. Month by month now, I think, at some point in this year, the construction segment will turn. Uh, it's perhaps not in quarter two, maybe more quarter three, quarter four. At the same time, the general engineering segment slowed a little bit. Now, in Q1, I don't expect that to be very dramatic. I think it's going to be more of a soft landing or a short period of decline there, but it's likely to be a little bit softer in quarter two as well. Uh. And then you still have a. In Life Science, you have Process, Energy & Water, which will continue to be in a good mode. It's difficult to sum this up and give a very detailed answer, but there will be. Not least, the Easter effect had a positive impact on quarter two.

Patrik Johnson
48:19 - 48:58

So saying it, if you know a few other words, I think sequentially, you know, Q2 from Q1 will pick up if we don't have any sort of significant changes in the sort of general macro environment, Q2 will pick up from Q1, but there are still these tough references from last year. So, it will be difficult, of course, to show really good organic growth levels also in quarter two, but sequentially, there will be a pickup if there are no dramatic changes. Major changes.

48:58 - 48:58

Um.

49:01 - 49:32

Understood. And then, on the M&A side, if we look at the acquisitions made year to date, there's been, you know, three out of six within Life Science. You, of course, have an ambition that all divisions should contribute to the M&A targets. But right now, based on what you see in the market, are there any particular areas where you feel that, first of all, there are more opportunities? And second of all, from your side, where do you find things more interesting?

Bo Annvik
49:34 - 50:31

Even if we have had a setback in Q1. Now, in terms of EBITA margins, that is a very interesting area. It's usually healthy profitability levels in the sector. Good gross margins in the sector and a generally less volatile environment, I would say as well. So, that's absolutely interesting and important. But we are broadly optimistic in terms of our acquisition approach. So, we look for really nice, good companies in all these sectors, and don't really put a certain sector as a priority. It's more about finding really good individual companies, I would say. And that should be possible in all areas, based on the geographical scope we have.

50:34 - 50:57

Understood. And then, my final one. Getting back to the subject we've already discussed quite a bit, but when it comes to the matter of the expense levels historically, how quickly would you assess that your businesses can, well, get back to being on their toes if we put it in that way.

50:59 - 50:59

Yes.

Bo Annvik
51:01 - 51:33

Rather quickly, I would say more quickly than anticipated. Large industrial companies with integrated product ranges. So, they can impact their activity-based costs very quickly, I would say. And, a bit more slowly, their semi-fixed costs. But what can also impact that. So, hopefully, we'll see some effect quite quickly.

51:35 - 51:38

Understood. That's all from my side. Thanks. Thanks.

Carl Boqvist
51:44 - 52:48

The next question comes from Johan Dahl from Danske Bank. Please go ahead, Johan Dahl, Danske Bank. Your line is now unmuted. Please go ahead. As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any written questions and closing comments.

Bo Annvik
52:50 - 53:04

Thank you. As we haven't received any written questions, we say thank you for listening in and please turn to us if you have complementary questions later on today, and we wish you a good day. Thank you so much.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…